Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia

被引:32
作者
Miesel, Lynn [1 ]
Cushion, Melanie T. [2 ,3 ]
Ashbaugh, Alan [2 ,3 ]
Lopez, Santiago R. [4 ]
Ong, Voon [5 ]
机构
[1] Pharmacol Discovery Serv, Taipei, Taiwan
[2] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[3] Cincinnati VAMC, Cincinnati, OH USA
[4] TransPharm Preclin Solut Inc, Jackson, MI USA
[5] Cidara Therapeut Inc, San Diego, CA 92121 USA
关键词
Aspergillus; Candida; Pneumocystis; antifungal agents; antifungal therapy; echinocandin; prophylaxis; LONG-ACTING ECHINOCANDIN; ACUTE MYELOID-LEUKEMIA; ANTIFUNGAL PROPHYLAXIS; FUNGAL-INFECTIONS; CELL TRANSPLANTATION; DOUBLE-BLIND; CASPOFUNGIN; CD101; DISEASES; AGENTS;
D O I
10.1128/AAC.01992-20
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Antifungal prophylaxis is recommended to prevent invasive fungal disease caused by Candida spp., Aspergillus spp., and Pneumocystis jirovecii in patients at risk for opportunistic infections, such as allogeneic blood or marrow transplant recipients, patients with hematological disease undergoing chemotherapy, or patients on immunosuppressive therapies. Current approaches to antifungal prophylaxis require multiple agents to cover these key fungi. Rezafungin, a novel echinocandin designed for next-generation properties (e.g., greater stability and long-acting pharmacokinetics for once-weekly dosing), has demonstrated in vitro activity against Candida and Aspergillus spp. and efficacy against Pneumocystis spp. biofilms. Rezafungin was evaluated in in vivo studies of prophylactic efficacy using immunosuppressed mouse models of invasive candidiasis, aspergillosis, and Pneumocystis pneumonia. Rezafungin reduction of Candida CFU burden was generally greater with increasing drug concentrations (5, 10, or 20 mg/kg) and when rezafungin was administered closer to the time of fungal challenge (day -1, -3, or -5). Similarly, in the aspergillosis model, survival rates increased with drug concentrations and when rezafungin was administered closer to the time of fungal challenge. Against Pneumocystis murina, rezafungin significantly reduced trophic nuclei and asci counts at all doses tested. Rezafungin prevented infection at the two higher doses compared to vehicle and had comparable activity to the active control trimethoprim-sulfamethoxazole at human equivalent doses for prevention. These findings support phase 3 development of rezafungin and the potential for single-agent prophylaxis against invasive fungal disease caused by Candida spp., Aspergillus spp., and Pneumocystis jirovecii.
引用
收藏
页数:8
相关论文
共 57 条
[1]   Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments [J].
Agarwal, Suresh K. ;
DiNardo, Courtney D. ;
Potluri, Jalaja ;
Dunbar, Martin ;
Kantarjian, Hagop M. ;
Humerickhouse, Rod A. ;
Wong, Shekman L. ;
Menon, Rajeev M. ;
Konopleva, Marina Y. ;
Salem, Ahmed Hamed .
CLINICAL THERAPEUTICS, 2017, 39 (02) :359-367
[2]   Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice [J].
Aslam, Saima ;
Rotstein, Coleman .
CLINICAL TRANSPLANTATION, 2019, 33 (09)
[3]  
Astellas Pharma US, 2019, MYC MIC SOD PACK INS
[4]   Prevention and Treatment of Cancer-Related Infections, Version 2.2016 [J].
Baden, Lindsey Robert ;
Swaminathan, Sankar ;
Angarone, Michael ;
Blouin, Gayle ;
Camins, Bernard C. ;
Casper, Corey ;
Cooper, Brenda ;
Dubberke, Erik R. ;
Engemann, Ashley Morris ;
Freifeld, Alison G. ;
Greene, John N. ;
Ito, James I. ;
Kaul, Daniel R. ;
Lustberg, Mark E. ;
Montoya, Jose G. ;
Rolston, Ken ;
Satyanarayana, Gowri ;
Segal, Brahm ;
Seo, Susan K. ;
Shoham, Shmuel ;
Taplitz, Randy ;
Topal, Jeffrey ;
Wilson, John W. ;
Hoffmann, Karin G. ;
Smith, Courtney .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (07) :882-913
[5]   Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris [J].
Berkow, Elizabeth L. ;
Lockhart, Shawn R. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 90 (03) :196-197
[6]   Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].
Brahmer, Julie R. ;
Lacchetti, Christina ;
Schneider, Bryan J. ;
Atkins, Michael B. ;
Brassil, Kelly J. ;
Caterino, Jeffrey M. ;
Chau, Ian ;
Ernstoff, Marc S. ;
Gardner, Jennifer M. ;
Ginex, Pamela ;
Hallmeyer, Sigrun ;
Chakrabarty, Jennifer Holter ;
Leighl, Natasha B. ;
Mammen, Jennifer S. ;
McDermott, David F. ;
Naing, Aung ;
Nastoupil, Loretta J. ;
Phillips, Tanyanika ;
Porter, Laura D. ;
Puzanov, Igor ;
Reichner, Cristina A. ;
Santomasso, Bianca D. ;
Seigel, Carole ;
Spira, Alexander ;
Suarez-Almazor, Maria E. ;
Wang, Yinghong ;
Weber, Jeffrey S. ;
Wolchok, Jedd D. ;
Thompson, John A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+
[7]  
Brown JM, 2019, BIOL BLOOD MARROW TR, V25
[8]   A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients [J].
Bruggemann, R. J. M. ;
Van der Velden, W. J. F. M. ;
Knibbe, C. A. J. ;
Colbers, A. ;
Hol, S. ;
Burger, D. M. ;
Donnelly, J. P. ;
Blijlevens, N. M. A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (04) :1166-1174
[9]  
Butts A, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00504-18, 10.1128/aac.00504-18]
[10]   A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study) [J].
Cattaneo, Chiara ;
Monte, Simona ;
Algarotti, Alessandra ;
Audisio, Ernesta ;
Borlenghi, Erika ;
Campiotti, Leonardo ;
Cerqui, Elisa ;
Fanizza, Caterina ;
Giuliani, Rachele ;
Mico, Caterina ;
Rocconi, Roberta ;
Salvi, Anna ;
Salvi, Flavia ;
Verga, Luisa ;
Levis, Alessandro ;
Deliliers, Giorgio Lambertenghi ;
Pogliani, Enrico M. ;
Tognoni, Gianni ;
Rambaldi, Alessandro ;
Rossi, Giuseppe .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (09) :2140-2145